Jilin Shenrui Medical Technology Co., Ltd. is a nationwide professional service provider specializing in clinical trial subject recruitment and full-cycle management. We deliver compliant, efficient and precise end-to-end services for domestic pharmaceutical enterprises, medical device manufacturers, CRO firms and clinical trial institutions of Grade A tertiary hospitals across China. By accelerating pharmaceutical innovation and connecting patients with cutting-edge therapeutic options, we have grown into an authoritative benchmark enterprise in China’s clinical trial recruitment sector.
Taking compliance as the fundamental principle, the Company has established an industry-leading full-process compliance management system. All workflows, communication scripts and documents undergo dual reviews in strict compliance with national regulations and GCP standards to safeguard subject rights and project compliance from the source. As a technology-driven enterprise, we independently developed the Ruizhiyu intelligent matching platform. Supported by an in-house high-quality subject database, the platform adopts the combination of algorithm matching and manual recheck to realize rapid preliminary patient screening and greatly shorten recruitment cycles. Our business covers more than ten core clinical departments such as oncology and hematology, with nearly a hundred patients successfully matched with appropriate clinical trials.
To guarantee precise and efficient service delivery, we implement a rigorous qualification management system for recruitment staff. All practitioners must complete standardized training and obtain relevant professional certifications before employment to secure consistent service quality. Meanwhile, we cooperate with caring enterprises including Yijia Group and Zhongan Rescue Group to transform diversified offline terminals into subject application portals. Such expansion of recruitment channels enables precise upstream screening and makes high-quality clinical trial resources accessible to more needy patients.
Supported by solid professional competence, the Company has built long-term stable partnerships with numerous top domestic pharmaceutical companies and Grade A tertiary hospitals nationwide, forming a tripartite win-win ecosystem linking pharmaceutical enterprises, hospitals and patients. Riding on China’s booming pharmaceutical innovation, we focus on clinical trial services for innovative medicines targeting severe illnesses and intractable chronic diseases to facilitate the commercial launch of more new drugs. Going forward, we will continuously upgrade technologies and expand our nationwide service network. Leveraging professional qualifications, technological empowerment and abundant industrial resources, we strive to resolve the last-mile challenge in pharmaceutical innovation and contribute sustained value to the high-quality development of the biomedical industry and public healthcare.
分享文章
